Profile data is unavailable for this security.
About the company
Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). It operates through Fumouze Diagnostics and SR2B.
- Revenue in EUR (TTM)93.05m
- Net income in EUR-13.79m
- Incorporated2005
- Employees560.00
- LocationBiosynex SA22 Boulevard Sebastien BrantILLKIRCH-GRAFFENSTADEN 67400FranceFRA
- Phone+33 388787887
- Fax+33 388787678
- Websitehttps://www.biosynex.com
Mergers & acquisitions
Acquired company | ALBIO:PAR since announced | Transaction value |
---|---|---|
ProciseDx Corp | -54.35% | -- |
Laboratoires Innoxa SAS-Eye Activity | -56.13% | -- |